Reimagining Medicine
Company overview
Innovation: Pipeline overview
Abbreviations
Financial review
Financial performance
Conclusions
Appendix
Innovation: Clinical trials
References
Abbreviations
ΑΙ
АІН
aHUS
ALL
ALS
AML
Auto-injector
Autoimmune hepatitis
atypical Hemolytic Uremic Syndrome
Acute lymphoblastic leukemia
Amyotrophic lateral sclerosis
Acute myeloid leukemia
IgAN
IPF
ITP
LBCL
BC
Breast cancer
LN
mCRPC
MDS
IgA nephropathy
Idiopathic pulmonary fibrosis
Immune thrombocytopenia
Large B-cell lymphoma
Lupus nephritis
Metastatic castration-resistant prostate cancer
Myelodysplastic syndrome
C3G
C3 glomerulopathy
MHSPC
Metastatic hormone sensitive prostate cancer
CART
Chimeric androgen receptor T
mPDAC
Metastatic pancreatic ductal adenocarcinoma
CLL
Chronic lymphocytic leukemia
CML
Chronic myeloid leukemia
MS
NASH
Multiple sclerosis
CRC
Colorectal cancer
nmCRPC
COPD
Chronic obstructive pulmonary disease
NPR1
COSP
Chronic ocular surface pain
nr-axSpA
CSU
Chronic spontaneous urticaria
NSAI
CVRR-Lp(a)
CVRR-LDLC
DME
Secondary prevention of cardiovascular events in patients with elevated levels of lipoprotein (a)
Secondary prevention of cardiovascular events in patients with elevated levels of LDLC
Diabetic macular edema
NSCLC
Non-alcoholic steatohepatitis
Non-metastatic castration-resistant prostate cancer
Natriuretic peptide receptor 1
Non-radiographic axial spondyloarthritis
Non-steroidal aromatase inhibitor
Non-small cell lung cancer
OS
Overall survival
PFS
Prefilled syringe
DLBCL
Diffuse large B-cell lymphoma refractory
PNH
Paroxysmal nocturnal haemoglobinuria
ESCC
FL
GCA
GVHD
GRPR
HCC
HD
Esophageal squamous-cell carcinoma
Follicular lymphoma
Giant cell arteritis
Graft-versus-host disease
Gastrin releasing peptide receptor
Hepatocellular carcinoma
Huntington's disease
PsA
Psoriatic arthritis
rHR
Resistant hypertension
rMS
rPFS
SLE
Relapsing multiple sclerosis
Radiographic progression free survival
Systemic lupus erythematosus
SMA Type 1
Spinal muscular atrophy (IV formulation)
HR LBCL
High risk large B-cell lymphoma
SpA
IA
Interim analysis
T1DM
SMA Type 2/3
Spinal muscular atrophy (IT formulation)
Spondyloarthritis
Type 1 Diabetes mellitus
iAMD
Intermediate age-related macular degeneration
WAIHA
Warm autoimmune hemolytic anemia
IC-MPGN
Immune complex membranoproliferative glomerulonephritis
89 Investor Relations | Q2 2023 Results
U NOVARTIS | Reimagining MedicineView entire presentation